Edition:
India

Advicenne SA (ADVIC.PA)

ADVIC.PA on Paris Stock Exchange

7.86EUR
25 Nov 2020
Change (% chg)

-- (--)
Prev Close
€7.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,479
52-wk High
€11.15
52-wk Low
€5.00

Latest Key Developments (Source: Significant Developments)

Advicenne Updates On ADV7103
Monday, 25 May 2020 

May 26 (Reuters) - ADVICENNE SA ::SAID ON MONDAY IN EUROPE, REVIEW OF MARKETING APPLICATION TO EMA FOR ADV7103 IN THE TREATMENT OF DISTAL RENAL TUBULAR ACIDOSIS (DRTA) PROCEEDS AS PLANNED, WITH AN ANTICIPATED POSITIVE OPINION IN THIS FIRST INDICATION AT THE END OF 2020.OBJECTIVE FOR ADV7103 APPLICATION: TO OBTAIN EUROPEAN UNION APPROVAL FOR “DISTAL TUBULOPATHIES” INDICATION IN EARLY 2021.IN US, PIVOTAL PHASE II/III ARENA-2 CLINICAL TRIAL EVALUATING ADV7103 IN DRTA TREATMENT COULD NOT BE PURSUED DURING COVID-19 CRISIS, BUT IS EXPECTED TO RESUME IN FALL WITH A SIMPLIFIED PROTOCOL.  Full Article

Advicienne Appoints Andre Ulmann Interim CEO
Friday, 13 Mar 2020 

March 13 (Reuters) - ADVICENNE SA ::ADVICENNE ANNOUNCES THE APPOINTMENT OF ANDRE ULMANN AS INTERIM CHIEF EXECUTIVE OFFICER.LUC-ANDRE GRANIER HAS LEFT HIS ROLE AS CEO OF COMPANY.SEARCH FOR A PERMANENT CEO IS ONGOING.  Full Article

Advicenne Says EMA Granted ADV7103 Orphan Drug Designation
Wednesday, 18 Dec 2019 

Dec 18 (Reuters) - Advicenne SA ::ANNOUNCED THAT ITS LEAD DRUG CANDIDATE, ADV7103, HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY EUROPEAN MEDICINES AGENCY (EMA) FOR TREATMENT OF CYSTINURIA IN EUROPE..ADV7103 AND IS CURRENTLY IN PHASE III TRIALS FOR THIS INDICATION IN UNITED STATES AND CANADA.  Full Article

Advicenne To Appoint David Horn Solomon As Chairman Of The Board
Friday, 15 Nov 2019 

Nov 15 (Reuters) - Advicenne SA ::ADVICENNE INTENDS TO APPOINT DAVID HORN SOLOMON AS CHAIRMAN OF THE BOARD OF DIRECTORS IN LINE WITH ITS INTERNATIONAL STRATEGY.ADVICENNE ORDINARY SHAREHOLDERS' MEETING CONVENED ON DECEMBER 20, 2019, FOR THIS PURPOSE.DR LUC-ANDRÉ GRANIER WILL REMAIN CHIEF EXECUTIVE OFFICER AS WELL AS A MEMBER OF BOARD OF DIRECTORS OF COMPANY.  Full Article

Advicenne Signs Agreement With Elaiapharm Lundbeck For Manufacturing Of ADV7103
Wednesday, 4 Sep 2019 

Sept 4 (Reuters) - ADVICENNE SA ::ANNOUNCES THAT IT HAS SIGNED A SUPPLY AGREEMENT WITH THE PHARMACEUTICAL CDMO ELAIAPHARM LUNDBECK FOR THE MANUFACTURING OF ITS LEAD PRODUCT.  Full Article

Advicenne: 1st Patient Enrolled In US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 In dRTA
Thursday, 29 Aug 2019 

Aug 29 (Reuters) - ADVICENNE SA ::ADVICENNE ANNOUNCES FIRST PATIENT ENROLLED IN US ARENA-2 PIVOTAL PHASE III CLINICAL TRIAL EVALUATING ADV7103 IN DISTAL RENAL TUBULAR ACIDOSIS (DRTA).ARENA-2 TRIAL IS EXPECTED TO INCLUDE APPROXIMATELY 40 PATIENTS.ADVICENNE HAS ALSO FILED AN APPLICATION FOR ORPHAN DRUG DESIGNATION (ODD) FOR ADV7103 IN UNITED STATES.ARENA-2: 8 STUDY CENTERS ARE ALREADY OPEN AND RESULTS ARE EXPECTED IN BEGINNING OF 2021.PRESENT STUDY WAS INITIATED FOLLOWING A EUROPEAN ARENA-1 CLINICAL TRIAL THAT DEMONSTRATED POSITIVE RESULTS AFTER 24 MONTHS OF TREATMENT.  Full Article

Advicenne To List On Regulated Market Of Euronext Brussels
Thursday, 23 May 2019 

May 23 (Reuters) - ADVICENNE SA ::ADVICENNE ANNOUNCES ITS INTENTION TO LIST ON THE REGULATED MARKET OF EURONEXT BRUSSELS.ADVICENNE SHARES WILL BE TRADABLE ON REGULATED MARKET OF EURONEXT BRUSSELS AS FROM MID-JUNE 2019 WITH UNCHANGED IDENTIFICATION CODES.COMPANY WOULD THUS BENEFIT FROM A CROSS LISTING ON THE TWO LARGEST EURONEXT MARKETS FOR COMPANIES IN THE LIFE SCIENCES SECTOR.CROSS LISTING WOULD HAVE NO IMPACT ON CURRENT SHAREHOLDERS AND EURONEXT PARIS REMAINS ADVICENNE'S PRIMARY LISTING VENUE.  Full Article